Atherosclerosis-prone apoE deficient mice were administrated IL-25 during both early (10–14 weeks of age) and late (21–25 weeks of age) stages of atherosclerosis to evaluate if IL-25 have any influence on the plaque initiation or plaque progression (Fig. 1). This evidence concerns the gene APOE and atherosclerosis.